Search results
Results from the WOW.Com Content Network
Quest Diagnostics (NYSE: DGX) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the ...
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics (DGX) closed the most recent trading day at $118.40, moving -0.08% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.22%.
Stock name Symbol Country of origin Q2 Holdings, Inc. QTWO: US Qiagen N.V. QGEN: Netherlands: Quad/Graphics, Inc. QUAD: US Quaker Chemical Corporation: KWR: US Quanex Building Products Corporation NX: US Quanta Services Inc. PWR: US Quantum FinTech Acquisition Corporation QFTA: US Quantum FinTech Acquisition Corporation QFTA.UN: US QuantumScape ...
Looking ahead to 2025, Quest Diagnostics projects revenue in the range of $10.70 billion to $10.85 billion, indicating continuous growth. The adjusted diluted EPS guidance stands between $9.55 and ...
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States , Puerto Rico , Mexico , and Brazil . [ 3 ] Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera , spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.